Intragenic ERBB2 kinase mutations in tumours

Philip Stephens; Chris Hunter; Graham R. Bignell; Sarah Edkins; Helen Davies; Jon W. Teague; Claire Stevens; Sarah O’Meara; Raffaella Smith; Adrian G. Parker; Andy Barthorpe; Matthew J. Blow; Lisa Brackenbury; Adam P. Butler; Oliver B. Clarke; Jennifer Cole; Ed Dicks; Angus Dike; Anja Drozd; Ken Edwards; Simon Forbes; Rebecca R. Foster; Kristian Gray; Chris Greenman; Kelly Halliday; Katy Hills; Vivienne Kosmidou; Richard Lugg; Andy Menzies; Janet Perry; Robert Petty; Keiran Raine; Lewis Ratford; Rebecca Shepherd; Alexandra Small; Yvonne Stephens; Calli Tofts; Jennifer Varian; Sofie West; Sara Widaa; Andrew Yates; Francis Brasseur; Colin S. Cooper; Adrienne M. Flanagan; Margaret A. Knowles; Suet Yi Leung; David N. Louis; Leendert H. J. Looijenga; Bruce Malkowicz; Marco A. Pierotti; Bin Tean Teh; Georgia Chenevix‐Trench; Barbara L. Weber; Siu Tsan Yuen; Grace Harris; Peter Goldstraw; Andrew G. Nicholson; P. Andrew Futreal; Richard Wooster; Michael R. Stratton

doi:10.1038/431525b

Intragenic ERBB2 kinase mutations in tumours

Philip Stephens(Wellcome Sanger Institute), Chris Hunter(Wellcome Sanger Institute), Graham R. Bignell(Wellcome Sanger Institute), Sarah Edkins(Wellcome Sanger Institute), Helen Davies(Wellcome Sanger Institute), Jon W. Teague(Wellcome Sanger Institute), Claire Stevens(Wellcome Sanger Institute), Sarah O’Meara(Wellcome Sanger Institute), Raffaella Smith(Wellcome Sanger Institute), Adrian G. Parker(Wellcome Sanger Institute), Andy Barthorpe(Wellcome Sanger Institute), Matthew J. Blow(Wellcome Sanger Institute), Lisa Brackenbury(Wellcome Sanger Institute), Adam P. Butler(Wellcome Sanger Institute), Oliver B. Clarke(Wellcome Sanger Institute), Jennifer Cole(Wellcome Sanger Institute), Ed Dicks(Wellcome Sanger Institute), Angus Dike(Wellcome Sanger Institute), Anja Drozd(Wellcome Sanger Institute), Ken Edwards(Wellcome Sanger Institute), Simon Forbes(Wellcome Sanger Institute), Rebecca R. Foster(Wellcome Sanger Institute), Kristian Gray(Wellcome Sanger Institute), Chris Greenman(Wellcome Sanger Institute), Kelly Halliday(Wellcome Sanger Institute), Katy Hills(Wellcome Sanger Institute), Vivienne Kosmidou(Wellcome Sanger Institute), Richard Lugg(Wellcome Sanger Institute), Andy Menzies(Wellcome Sanger Institute), Janet Perry(Wellcome Sanger Institute), Robert Petty(Wellcome Sanger Institute), Keiran Raine(Wellcome Sanger Institute), Lewis Ratford(Wellcome Sanger Institute), Rebecca Shepherd(Wellcome Sanger Institute), Alexandra Small(Wellcome Sanger Institute), Yvonne Stephens(Wellcome Sanger Institute), Calli Tofts(Wellcome Sanger Institute), Jennifer Varian(Wellcome Sanger Institute), Sofie West(Wellcome Sanger Institute), Sara Widaa(Wellcome Sanger Institute), Andrew Yates(Wellcome Sanger Institute), Francis Brasseur(Ludwig Cancer Research), Colin S. Cooper(Institute of Cancer Research), Adrienne M. Flanagan(University College London), Margaret A. Knowles(Cancer Research UK), Suet Yi Leung(Queen Mary Hospital), David N. Louis(Massachusetts General Hospital), Leendert H. J. Looijenga(Erasmus MC Cancer Institute), Bruce Malkowicz(University of Pennsylvania), Marco A. Pierotti(FIRC Institute of Molecular Oncology), Bin Tean Teh(Van Andel Institute), Georgia Chenevix‐Trench(QIMR Berghofer Medical Research Institute), Barbara L. Weber(University of Pennsylvania), Siu Tsan Yuen(University of Hong Kong), Grace Harris(Royal Brompton Hospital), Peter Goldstraw(Royal Brompton Hospital), Andrew G. Nicholson(Royal Brompton Hospital), P. Andrew Futreal(Wellcome Sanger Institute), Richard Wooster(Wellcome Sanger Institute), Michael R. Stratton(Wellcome Sanger Institute)

Nature

September 1, 2004

10.1038/431525b

Cited by 790

Abstract

Related Papers

No related papers found

Powered by citation graph analysis